(19)
(11) EP 2 858 670 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.09.2018 Bulletin 2018/37

(45) Mention of the grant of the patent:
08.08.2018 Bulletin 2018/32

(21) Application number: 13731306.0

(22) Date of filing: 11.06.2013
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
A61P 35/00(2006.01)
 A61K 39/395(2006.01)
C07K 16/24(2006.01)
(86) International application number:
PCT/EP2013/062070
(87) International publication number:
WO 2013/186236 (19.12.2013 Gazette 2013/51)

(54)

ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES

ANTAGONISTEN VON IL-17-ISOFORMEN UND DEREN VERWENDUNGEN

ANTAGONISTES D'ISOFORMES D'IL-17 ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.06.2012 WO PCT/EP2012/061134

(43) Date of publication of application:
15.04.2015 Bulletin 2015/16

(60) Divisional application:
18183281.7

(73) Proprietors:
  • Orega Biotech
    69130 Ecully (FR)
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
    75013 Paris (FR)

(72) Inventors:
  • ALBERICI, Gilles
    F-69290 Grezieu La Varenne (FR)
  • BASTID, Jérémy
    F-69290 Craponne (FR)
  • BENSUSSAN, Armand
    F-75013 Paris (FR)
  • BONNEFOY, Nathalie
    F-69003 Lyon (FR)
  • ELIAOU, Jean-François
    F-34070 Montpellier (FR)

(74) Representative: Cabinet Laurent & Charras 
Le Contemporain 50 Chemin de la Bruyère
69574 Dardilly Cedex
69574 Dardilly Cedex (FR)


(56) References cited: : 
WO-A1-2006/094384
WO-A2-2008/049070
WO-A2-2011/141823
 WO-A1-2010/116123
WO-A2-2011/044563
   
  • YAMAGUCHI YUMI ET AL: "IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 179, no. 10, 1 November 2007 (2007-11-01), pages 7128-7136, XP002629391, ISSN: 0022-1767
  • R. H. GOLDSTEIN ET AL: "Human Bone Marrow-Derived MSCs Can Home to Orthotopic Breast Cancer Tumors and Promote Bone Metastasis", CANCER RESEARCH, vol. 70, no. 24, 15 December 2010 (2010-12-15), pages 10044-10050, XP055043081, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-1254
  • TIMOTHY O'SULLIVAN,ROBERT SADDAWI-KONEFKA, AND JACK BUI: "IL-17D mediated cancer rejection", JOURNAL OF IMMUNOLOGY, vol. 188, no. 162, 26, 1 May 2012 (2012-05-01), XP009164360,
  • TANIA BENATAR ET AL: "IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 6, 13 December 2009 (2009-12-13), pages 805-817, XP019800201, ISSN: 1432-0851
  • YOICHIRO IWAKURA ET AL: "Functional Specialization of Interleukin-17 Family Members", IMMUNITY, vol. 34, no. 2, 25 February 2011 (2011-02-25), pages 149-162, XP028176128, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2011.02.012 [retrieved on 2011-02-11]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).